ARTICLE | Clinical News
Undisclosed intranasal compound: Phase I started
August 18, 2008 7:00 AM UTC
Serenity began a Phase I trial. The compound was developed using the CPE-215 drug delivery technology from CPEX, which spun out from Bentley Pharmaceuticals Inc. (AMEX:BNT, Exeter, N.H.) earlier this...